All projects Alzheimer Europe is currently involved are listed here. For news about these projects, see here: http://alzheimer-europe.org/News/EU-projects
AE: The ethical implications of recognising dementia as a disability
In 2017, Alzheimer Europe will continue to develop its European Dementia Ethics Network. The ethical implications of recognising dementia as a disability have been identified as the priority for its work this year. A working group will be set up comprised of ethicists, clinicians, researchers, people with dementia, carers and representatives from Alzheimer associations. The group will meet twice in the course of the year to discuss the ethical issues related to the recognition of dementia as a disability. This will lead to the publication of a report in December containing the results of the literature review and the position of Alzheimer Europe on this issue.
AE: Dementia in Europe Yearbook 2017
In 2017, AE will continue to compare policies and practice that are relevant to people with dementia across Europe. This year, the comparative report will identify care provision for people with dementia with a focus on standards for care services. This will lead to the publication of national reports, a comparative report and the identification of best practices in this field.
AE: Clinical Trial Watch (CTW)
The purpose of the CTW is to provide accessible and up-to-date information on clinical trials that are investigating drugs for Alzheimer’s disease and/or dementia. At a first stage of the project, only clinical trials in phase III and that are currently recruiting participants in two or more European countries will be included in the CTW. Alzheimer Europe and its EWGPWD have designed and developed the contents of the summary reports that will be included in the CTW. The sponsors of the clinical trials have also been consulted on the information contained on the reports. The CTW will be active from July 2016.
AE: Guidelines Watch
During 2014 and 2015 Alzheimer Europe has collected information on existing national guidelines for the diagnosis, treatment and management of dementia in Europe. In 2016, Alzheimer Europe will make this information available to its members through an internal database.
The NILVAD project team is conducting a phase 3 clinical trial of Nilvadipine, an existing hypertension drug, in people with mild to moderate Alzheimer’s disease. Previous research showed that the drug also blocks production of the amyloid protein that is believed to be central to the Alzheimer’s disease process. The trial is being conducted in 21 study sites in nine European countries on 500 participants who are receiving the drug or a placebo over an 18 month period.
The European Medical Information Framework project is connecting data on 52 million individuals to decipher links between genetic background, biological abnormalities, brain imaging changes, mental symptoms and disease progression. The main objective is to create an environment that allows for efficient re-use of existing health data. Currently, the project includes two specific therapeutic research topics including the onset of Alzheimer’s disease. This topic aims to discover and validate biomarkers of AD onset and also identify high-risk individuals for therapeutic trials for prevention.
PredictND (an acronym for From Patient Data to Clinical Diagnosis in Neurodegenerative Diseases) is a four year, EUR 4.2 million project that started in January 2014. Its primary aim is to develop tools and means for earlier, evidence-based and data-driven diagnosis of a range of neurodegenerative diseases (NDs) such as Alzheimer's disease, vascular dementia and fronto-temporal dementia. This novel approach will be tested on 800 patients in four hospitals in Finland, Denmark, the Netherlands and Italy. The PredictND project is coordinated by VTT Technical Research Centre of Finland and is funded by the EU.
The PACE project will describe and compare the effectiveness of healthcare systems in six European countries with (Belgium, Netherlands, UK) and without (Finland, Italy, Poland) formal palliative care structures for long-term care facilities in terms of patient and family outcomes, quality of palliative care and cost-effectiveness, and in terms of staff knowledge, practices and attitudes. This will involve mapping palliative care systems across Europe, a retrospective, representative cross-sectional study of deaths in long-term care facilities in each of the six participating countries and an interventional study measuring the impact of training on the quality of the end-of-life experience.
AETIONOMY is a five-year project that began in February 2014. It aims to identify subgroups of dementia and Parkinson’s disease - based on the underlying genetic or molecular causes of the variants - in order to allow tailored therapies. The project will involve the collection of clinical data, imaging and genetic data and will create a new way to combine all of these together to look for patterns which could identify sub-groups of patients with similar causes of their disease.
The European Prevention of Alzheimer’s dementia (EPAD) initiative is a collaborative research effort to improve the chance of successfully preventing Alzheimer’s dementia and to better understand early aspects of Alzheimer’s disease before dementia develops. The goal of the initiative is the prevention of dementia in people with evidence of the disease (such as biomarker abnormalities) who still may have little or no complaints or clinical symptoms. EPAD will establish a European-wide cohort of over 6,000 participants, of which 1,500 will be invited to participate in a trial to test new treatments for the prevention of Alzheimer’s dementia. The five year programme is part of the Innovative Medicines Initiative, a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA.
The four year SMART4MD project will develop an app called Support, Monitoring and Reminder Technology for Mild Dementia (SMART4MD). The app will be designed to help people with mild dementia adhere to treatment regimens as well as allowing them to share health-related data with their carers and doctors. As well as giving people more control over their care, the aim is to slow cognitive and functional decline and to reduce pressure on carers as well as costs for healthcare providers, through use of the app. It will be piloted with 1,100 volunteers from several EU countries.
SyDAD (Synaptic Dysfunction in Alzheimer's Disease) is a European Training Network, sponsored by Horizon 2020 Marie Sklodowska Curie Actions. The research programme will focus on synaptic dysfunction, the main connection point between pathology and cognitive decline in Alzheimer’s disease. It will support and train 15 Early Stage Researchers (ESRs, PhD students) with an interest in the area of Alzheimer’s disease and synaptic dysfunction, focusing on new drugs and biomarkers. The project is led by the Department of Neurobiology, Care Sciences and Society at Karolinska Institutet (Sweden).
INDUCT (Interdisciplinary Network for Dementia Utilising Current Technology) is a four year project under the Marie Sklodowska-Curie Actions Programme. The main aim of INDUCT is to develop a premier quality multi-disciplinary, multi-professional and intersectorial education and training research framework for Europe aimed at improving technology and care for people with dementia, and to use the coherent themes and interrelated Early Stage Researchers ESRs within INDUCT to provide the evidence to show how technology can improve the lives of people with dementia.
MinD (Designing for People with Dementia) is a four year project under the Marie Sklodowska-Curie Actions Programme. It aims to help people with dementia engage in social contexts to improve psychosocial wellbeing. Design can offer novel ways of complementing existing care approaches to empower people with dementia in everyday social situations. The project partners will use the concept of mindful design to investigate innovative design solutions, in order to enable self-empowerment and confidence building of people living with dementia. There will be two focus areas: a) personal difficulties with social interaction and b) environmental influences on social engagement. In these two contexts, we will study how personal, wearable designs can help mediate perceptions of identity and emotion management; and how environmental aspects can reduce feelings of information overload and instill feelings of self-empowerment and control.
The "Amyloid imaging to prevent Alzheimer’s disease" project aims to improve the diagnostic workup of patients suspected to have Alzheimer's disease and their management. The partners aim to improve knowledge of the natural history of AD in a pre-symptomatic stage, in order to better select patients for trials. In addition, they will monitor changes in beta amyloid deposition in the brain, in order to quantify the impact of novel therapies.
DEM 2 - 2nd European Joint Action on Dementia (2016-2017)
The aim of the 2nd European Joint Action on Dementia, known as Dementia Two or DEM 2, is to promote the implementation in EU Member States of coordinated actions to improve the situation of people living with dementia and their carers. These actions were identified by ALCOVE, the first European Joint Action on Alzheimer Cooperative Valuation in Europe, whose partners built a wealth of evidence and knowledge to support Member States in developing their dementia policies and operational capacity. DEM 2 will focus on four key areas for action: diagnosis and post diagnostic support, crisis and care coordination, residential care and dementia-friendly communities.
The "Real world outcomes across the Alzheimer’s disease spectrum for better care: multi-modal data access platform" project will provide the foundation for an integrated data environment and framework for real world evidence (RWE) in Alzheimer's disease. This will include the development of consensual key outcome measures and data integration tools for dataset characterisation and outcome classification, as well as guidelines on the handling and interpretation of RWE data. ROADMAP has a budget of EUR €7.77 million and 22 partners led by the University of Oxford and Novartis.
Last Updated: Friday 06 January 2017